







# Non-motor symptoms and activities of daily living in Parkinson's Disease

Sara Becker, M.Sc.

12. October. 2018

# Non-motor symptoms (NMS) in Parkinson's Disease (PD)

- Contribute to reduced quality of life and disability
  - Often reported as more disabling than motor symptoms

- Prevalence of at least one NMS:
  - Barone et al. (2009): 98.6% of 1072 patients
  - ► Kim et al. (2013): 100% of 131 patients
  - ▶ Bugalho et al. (2016): 97.7% of 134 patients
  - ► Salari et al. (2017): 100% of 81 patients

#### 3 Frequency of occurrence of a range of non-motor symptoms (NMS)\*<sup>15</sup>

Non-motor symptoms	Mean	Range					
Cognitive							
Memory	46%	38-63%					
Concentration	39%	30-50%					
Depression							
Sadness	43%	23-56%					
Anxiety	43%	31-56%					
Sleep							
Excessive daytime sleepiness	31%	21-37%					
Insomnia	41%	18-53%					
REM sleep behaviour disorder	34%	30-39%					
Restless legs syndrome	36%	28-41%					
Fatigue	42%	31-58%					
Pain	31%	18-46%					
Gastrointestinal							
Swallowing	25%	16-30%					
Constipation	47%	28-72%					
Urinary							
Urgency	53%	35-61%					
Nocturia	54%	26-67%					
NMS Questionnaire (global comparison)							
Parkinson disease patients	8	4-19					
Healthy controls 4 2–12							

REM = rapid eye movement. \* Based on international cohort studies using the Nonmotor Symptoms Questionnaire. Data for NMS Questionnaire (global comparison) are number of symptoms. ◆

Titova N & Chaudhuri KR. Med J Aust (2018)

#### "DASH" Score Naismith SL & Lewis SJ. J Clin Neurosci (2011)

- Items of the Parkinson's Disease Questionnaire (PDQ-39):
  - Depression
  - Anxiety
  - Sleep disturbances
  - Hallucinations

Summed into one score

Greater severity of DASH symptoms was strongly associated with poorer working memory and set-shifting (executive functions)

#### 53 PD patients without dementia

Coefficient	p
0.14	ns
0.31	0.024
0.30	0.032
0.87	0.000
0.76	0.000
-0.14	ns
-0,35	0.021
-0.45	0.001
-0,21	ns
-0.06	ns
-0.01	ns
0.45	0,001
	0.14 0.31 0.30 0.87 0.76 -0.14 -0.35 -0.45 -0.21 -0.06 -0.01

DASH score = sum of Depression, Anxiety, Sleep and Hallucinosis items from the PDQ-39, ns = not significant at p < 0.05, PDQ-39 = Parkinson's Disease Quality of Life Questionnaire, Trails B-A, Trailmaking Test Part B - Part A score.

#### Activities of Daily Living (ADL)

- Defined as activities necessary for independent living
  - ► Loss is a key feature of Parkinson's Disease Dementia (PDD)
- ADL decline has been linked to dementia in PD
- But: Symptoms of PD interfere with virtually all ADL
  - ▶ Diagnosis of PDD requires ADL deficits be caused by <u>cognitive</u>, not motor, symptoms

# The Functional Activities Questionnaire (FAQ) as an ADL measurement

- Constructed FAQ subscores
  - ► FAQ<sub>C</sub>: Cognitivedriven ADL impairment
  - ► FAQ<sub>M</sub>: Motor-driven ADL impairment

Writing checks, paying bills, balancing checkbook	С	
Assembling tax records, business affairs, or papers	С	
Shopping alone for clothes, household necessities, or groceries		M
Playing a game of skill, working on a hobby		M
Heating water, making a cup of coffee, turning off stove after use		M
Preparing a balanced meal		M
Keeping track of current events	С	M
Paying attention to, understanding, discussing TV, book, magazine	С	M
Remembering appointments, family occasions, holidays, medications	С	
Traveling out of neighborhood, driving, arranging to take buses		M
TOTAL SCORE:		

#### Aims


- 1. Can the DASH score differentiate between PD patients with and without mild cognitive impairment?
- 2. What is the association of the DASH score to other known risk factors for PDD (age, cognitive decline)?

3. What is the interaction between the DASH and ADL in PD?

Sponsored by: Janssen Pharmaceutica, Johnson & Johnson

## **ABC-PD Study:**

## Amyloid-beta in CSF as a risk factor for cognitive dysfunction in Parkinson's Disease





Abeta 1-42 pTau hTau



Family history of PD Concomitant diseases **Demographics** Lifestyle



PD-NMS-Q **BDI-II** PDQ-39 **FAQ** 

**ESS** QUIP PPBC/ICIQ-SF



**UPDRS-III** and IV Hoehn & Yahr Medication/LEDD **UKBB** criteria



**Sniffin Sticks** Vital parameters UMSARS I (9-12) **UPDRS-I-IV** 

PD-NMS-Scale (1-5) Pill-Questionnaire Cognitive assessment

#### Recruitment

Patients eligible/contacted

N= 802



N = 460 declined study participation

Patients who agreed to participate

N = 342



N= 56 excluded for participation

N= 31 withdrew consent for lumbar puncture

N= 11 withdrew consent for study participation

N= 13 diagnosis of atypical PD

N= 1 too young for inclusion

Lumbar puncture

N= 286



N= 60 excluded for data analyses

N= 16 newly diagnosed PDD based on our testing

N= 15 presence of concomitant neurological diseases

N= 25 signs of major depression

N= 2 previous alcohol abuse

N= 2 missing data





Patient data analyzed

N = 226

#### Neuropsychological Assessment

- Cognitive classification using Level II criteria
  - ► PD-CN, cognitively normal
  - PD-MCI, mild cognitive impairment in PD

Domain	Test	Subtest		
Global Cognitive	Mini-Mental State Examination			
Screening	Montreal Cognitive Assessment			
Attention & Working	Wechsler Adult Intelligence Scale	Digit-Symbol Test		
Memory	(WIE)	Letter-Number-Sequencing		
Memory	Consortium to Establish a Registry	Word List		
	For Alzheimer's Disease (CERAD-	Recall of Word List		
	PLUS)	Recall of Constructional Praxis		
Executive Functions	CERAD-PLUS	Semantic Fluency		
		Phonemic Fluency		
		Trail Making Test Part B		
Language	CERAD-PLUS	Boston Naming Test		
	WIE	Similarities		
Visuospatial Abilities	CERAD-PLUS	Constructional Praxis		
	Leistungsprüfsystem 50+ (LPS 50+)	Fragmented Words		

#### **DASH Score Construction**

	<b>DASH PDQ-39 (Naismith)</b> Symptoms based on scale from 0 (never) to 4 (always)	<b>DASH NMS-Scale</b> Symptoms assessed over last month, scored with respect to severity (0 none - 3 severe) and frequency (1 rarely - 4 very frequently)
	Due to having Parkinson/s Disease, how often during the last month have you	
Depression	17felt depressed?	3.10. Does the patient seem sad or depressed or has he/she reported such feelings?
Anxiety	21felt anxious?	3.9. Does the patient feel nervous, worried or frightened for no apparent reason?
Sleep Disturbances	30unexpectedly fallen asleep during the day?	2.3. Does the patient doze off or fall asleep unintentionally during daytime activities? (For example, during conversations, during mealtimes, or while watching television or reading)
Hallucinations	33had distressing dreams or hallucinations?	4.13. Does the patient indicate that he/she sees things that are not there?
Maximum Points	16	48


### Demographics

	Total sample N=226		PD-MCI n=94	<i>p</i> -value PD-CN vs. PD-MCI	
Male Gender: n (%)	145 (64.2)	85 (64.4)	60 (63.8)	1.00	
Age (years)	66.19 (48.07-83.67)	65.52 (48.07-79.93)	67.78 (50.01-83.67)	0.04	
Education Years	13 (8-21)	13 (8-21)	12 (8-21)	0.08	
Age at Onset (years)	60.58 (36.43-79.49)	60.03 (36.43-77.63)	61.29 (41.02-79.49)	0.21	
Disease Duration Years	3.88 (0-18.40)	3.64 (0.11-18.40)	4.87 (0-15.37)	0.08	
LEDD	487.13 (0-1574)	422.50 (0-1574)	542.50 (0-1380)	0.005	
UPDRS-III (0-108)	25 (1-56)	22 (1-56)	28.50 (3-52)	<0.001	
Hoehn & Yahr: n (%)				0.002	
1	30 (13.3)	22 (16.7)	8 (8.5)		
2	129 (57.1)	83 (62.9)	46 (48.9)		
3	65 (28.8)	26 (19.7)	39 (41.5)		
4	2 (0.9)	1 (0.8)	1 (1.1)		
BDI-II Score (0-20)	6 (0-19)	6 (0-19)	7 (0-19)	0.09	
MoCA (0-30)	26 (16-30)	27 (18-30)	25 (16-30)	<0.001	

Results are expressed as Median (Range), except where noted

#### Results

DASH-NMS score was significantly higher in the PD-MCI group compared to the PD-CN group (*p*=0.037)



#### Correlations with the DASH score

	$r_{s}$	<i>p</i> -value
Age	0.10	0.13
LEDD	0.06	0.36
UPDRS-III Total Score	0.11	0.09
MoCA Total Score	-0.23	<0.001
Executive Functions	-0.07	0.26
Attention/Working Memory	-0.18	0.006
Memory	-0.12	0.08
Visuspatial Functions	-0.19	0.005
Language	-0.13	0.05
FAQ <sub>C</sub>	0.28	<0.001
FAQ <sub>M</sub>	0.21	0.002

#### Regression Analysis

Results of the linear regression showed that the only statistically significant predictor of the DASH score was cognitive-driven ADL impairment (p=0.009)

				95 % Confidence Interval			
	B-weight	t	<i>p</i> -value	Lower Bound	Upper Bound		
MoCA	-0.06	-0.77	0.44	-0.29	0.13		
Attention/ Working Memory	-0.03	-0.39	-0.39 0.70 -1		0.72		
Visuospatial Functions	-0.13	-1.77	0.08	-1.33	0.07		
Language	0.07	0.89	0.37	-0.47	1.25		
FAQ <sub>C</sub>	0.26	2.64	0.009	2.65	18.32		
FAQ <sub>M</sub>	0.07	0.79	0.43	-4.52	10.55		

#### Conclusion

- ▶ DASH Score is related to severity of cognitive impairment
  - Primarily associated to cognitive-driven ADL impairment
- Combination of both factors may define a group of patients at risk for conversion to PDD
- ► Long-term studies are needed to evaluate the predictive value of the FAQ subscores as well as the DASH score
  - Currently in progress (4 year follow-up of our cohort)

#### Thank You to...

PD Dr. Inga Liepelt-Scarfone Prof. Dr. Daniela Berg Prof. Dr. Walter Maetzler AG Neurodegeneration

#### **ABC-PD Team:**

Alena Bäumer
Sarah Caliandro
Friederike Klumpp
Katja Michaelis
Susanne Nußbaum
Jessica Pollock
Maren Rüdiger-Albers
Patricia Sulzer
Zuzanna Tkaczynska
Ina Wiedmann



### Correlations DASH (expanded)

	DASH	Age	LEDD	UPDRS-III	МоСА	Executive Functions	Attention /Working Memory	Memory	Visuospatial Functions	Language	FAQ <sub>C</sub>	$FAQ_M$	$FAQ_{Q}$
DASH		.10	.06	.11	23**	07	18**	12	19**	13*	.28**	.21**	.05
Age	.10		.05	.04	41**	17**	11	08	.00	02	.14*	.09	.01
LEDD	.06	.05		.30**	07	09	08	08	16 <sup>*</sup>	13*	.12	.18**	08
UPDRS-III	.11	.04	.30**		19**	21**	27**	11	12	10	.18**	.38**	20**
MoCA	23**	41**	07	19**		.44**	.46**	.39**	.37**	.47**	27**	17*	13*
Executive Functions	07	17**	09	21**	.44**		.63**	.47**	.42**	.47**	23**	17*	05
Attention/ Working Memory	18**	11	08	27**	.46**	.63**		.39**	.40**	.48**	36**	26**	12
Memory	12	08	08	11	.39**	.47**	.39**		.37**	.33**	20**	13*	09
Visuospatial Functions	19**	.00	16*	12	.37**	.42**	.40**	.37**		.40**	18**	18**	02
Language	13*	02	13*	10	.47**	.47**	.48**	.33**	.40**		30**	22**	14*
FAQ <sub>C</sub>	.28**	.14*	.12	.18**	27**	23**	36**	20**	18**	30**		.57**	.43**
FAQ <sub>M</sub>	.21**	.09	.18**	.38**	17*	17*	26**	13*	18**	22**	.57**		36**
FAQ <sub>Q</sub>	.05	.01	08	20**	13*	05	12	09	02	14*	.43**	36**	

<sup>\*</sup>Correlation is significant at the 0.05 level

<sup>\*\*</sup> Correlation is significant at the 0.01 level

#### Presence of each DASH Symptom (extra)

Presence of
Depression was
statistically
significant
between PD-CN
and PD-MCI
groups
(p=0.041)

